Literature DB >> 15304049

A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.

C Longstaff1, C M Whitton.   

Abstract

A method has been developed for accurately and precisely measuring the activity of a range of plasminogen activators (PAs) used as thrombolytic agents, including streptokinase, tissue plasminogen activator (tPA) and variants, and urokinase (uPA), both single and two chain forms. Plasminogen activation is monitored in a transparent, solid fibrin matrix but uses chromogenic substrate hydrolysis, rather than changes in fibrin, to quantitate the activity of PAs. The method has been tested in two recent international collaborative studies involving tPA and streptokinase where it has been shown to perform very well. Furthermore, the method is based on sound enzymological principles and once correction for the competitive inhibition of fibrin(ogen) is made, the generation of plasmin can be determined in molar terms and hence the activity of PAs can be expressed and compared in SI units (rate of increase in molar concentration of plasmin) as well as International Units. The assay is also arranged in such a way to reflect the behavior of PAs in vivo during thrombolytic therapy and it is shown that the specific activity of streptokinase and tPA in this system reflects plasmin generation capacity of these thrombolytics for doses given in infusions for treatment of myocardial infarction. The method would make a suitable reference method for PAs and provides a rigorous means of studying and modeling the enzymology of fibrinolysis and will be helpful in the rational design of third generation thrombolytic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304049     DOI: 10.1111/j.1538-7836.2004.00816.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies.

Authors:  Colin Longstaff; Craig Thelwell; Stella C Williams; Marta M C G Silva; László Szabó; Krasimir Kolev
Journal:  Blood       Date:  2010-10-21       Impact factor: 22.113

2.  Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones.

Authors:  Colin Longstaff; Imre Varjú; Péter Sótonyi; László Szabó; Michael Krumrey; Armin Hoell; Attila Bóta; Zoltán Varga; Erzsébet Komorowicz; Krasimir Kolev
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

3.  Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components.

Authors:  Z Rottenberger; E Komorowicz; L Szabó; A Bóta; Z Varga; R Machovich; C Longstaff; K Kolev
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

4.  Fibrinolysis in a lipid environment: modulation through release of free fatty acids.

Authors:  G Rábai; B Váradi; C Longstaff; P Sótonyi; V Kristóf; F Timár; R Machovich; K Kolev
Journal:  J Thromb Haemost       Date:  2007-06       Impact factor: 5.824

5.  Constitutive optimized production of streptokinase in Saccharomyces cerevisiae utilizing glyceraldehyde 3-phosphate dehydrogenase promoter of Pichia pastoris.

Authors:  Ravi N Vellanki; Ravichandra Potumarthi; Kiran K Doddapaneni; Naveen Anubrolu; Lakshmi N Mangamoori
Journal:  Biomed Res Int       Date:  2013-09-22       Impact factor: 3.411

6.  Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.

Authors:  Sian Huish; Craig Thelwell; Colin Longstaff
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 7.  Measuring fibrinolysis: from research to routine diagnostic assays.

Authors:  C Longstaff
Journal:  J Thromb Haemost       Date:  2018-02-17       Impact factor: 5.824

8.  Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.

Authors:  András Kovács; László Szabó; Colin Longstaff; Kiril Tenekedjiev; Raymund Machovich; Krasimir Kolev
Journal:  Thromb Res       Date:  2013-09-21       Impact factor: 3.944

9.  Biosimilars: the process is the product. The example of recombinant streptokinase.

Authors:  C Thelwell; C Longstaff
Journal:  J Thromb Haemost       Date:  2014-07-31       Impact factor: 5.824

10.  Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics.

Authors:  Graham Roberts; Bernard Fox; Colin Longstaff
Journal:  Vox Sang       Date:  2020-09-28       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.